Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta

Bone

Volumn 50, Issue 3, 2012, Pages 784-791

  Davis, Mathieu S ^a   Kovacic, Bethany L ^a   Marini, Joan C ^c   Shih, Albert J ^a   Kozloff, Kenneth M ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Collagen; Fracture toughness; Microdamage; Mouse model; Osteogenesis imperfecta

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEFORMATION; BONE FRAGILITY; BONE INJURY; BONE REMODELING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FRACTURE; FRACTURE TOUGHNESS; MALE; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOGENESIS IMPERFECTA; SPECIES DIFFERENCE; ULNA; WILD TYPE;

ANIMALS; BIOMECHANICS; COLLAGEN; DISEASE MODELS, ANIMAL; MALE; MICE; OSTEOGENESIS IMPERFECTA; TENSILE STRENGTH; ULNA; WEIGHT-BEARING;

EID: 84856960350     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.12.007     Document Type: Article

References (47)

1. Rauch F., Glorieux F. Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
2. Byers P.H., Cole W.G. In connective tissue and its heritable disorders molecular, genetic and medical aspects. Osteogenesis imperfecta 2002, 385-430. Wiley-Liss, New York. 2nd ed. P.M. Royce, B. Steinmann (Eds.).
3. Avioli L.V. Metabolic bone disease and clinically related disorders 1998, Academic Press, San Diego. 3rd ed.
4. Marini J.C., Forlino A., Cabral W.A., Barnes A.M., Antonio J.D.S., Milgrom S., et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007, 28:209-221.
5. Morello R., Bertin T.K., Chen Y., Hicks J., Tonachini L., Monticone M., et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006, 127:291.
6. Barnes A.M., Chang W., Morello R., Cabral W.A., Weis M., Eyre D.R., et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med 2006, 355:2757.
7. Cabral W.A., Chang W., Barnes A.M., Weis M., Scott M.A., Leikin S., et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007, 39:359-365.
8. Brenner R.E., Vetter U., Bollen A.-M., Mörike M., Eyre D.R. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 2009, 9:993.
9. Baron R., Gertner J.M., Lang R., Vignery A. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983, 17:204.
10. Jepsen K.J., Goldstein S.A., Kuhn J.L., Schaffler M.B., Bonadio J. Type-I collagen mutation compromises the post-yield behavior of Mov13 long bone. J Orthop Res 1996, 14:493.
11. Dong X.N., Zoghi M., Ran Q., Wang X. Collagen mutation causes changes of the microdamage morphology in bone of an OI mouse model. Bone 2010, 47:1071-1075.
12. Forlino A., Porter F.D., Lee E.J., Westphal H., Marini J.C. Use of the cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an α1(I) G349C substitution. J Biol Chem 1999, 274:37923-37931.
13. Kozloff K.M., Carden A., Bergwitz C., Forlino A., Uveges T.E., Morris M.D., et al. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res 2004, 19:614-622.
14. Uveges T.E., Collin-Osdoby P., Cabral W.A., Ledgard F., Goldberg L., Bergwitz C., et al. Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res 2008, 23:1983-1994.
15. Lee K.C.L., Maxwell A., Lanyon L.E. Validation of a technique for studying functional adaptation of the mouse ulna in response to mechanical loading. Bone 2002, 31:407-412.
16. Bentolila V., Boyce T.M., Fyhrie D.P., Drumb R., Skerry T.M., Schaffler M.B. Intracortical remodeling in adult rat long bones after fatigue loading. Bone 1998, 23:275-281.
17. Torrance A.G., Mosley J.R., Suswillo R.F.L., Lanyon L.E. Noninvasive loading of the rat ulna in vivo induces a strain-related modeling response uncomplicated by trauma or periostal pressure. Calcif Tissue Int 1994, 54:241.
18. Boyce T.M., Fyhrie D.P., Glotkowski M.C., Radin E.L., Schaffler M.B. Damage type and strain mode associations in human compact bone bending fatigue. J Orthop Res 1998, 16:322.
19. Fritton S., Rubin C. Bone mechanics handbook 2001, Boca Raton, FL.
20. Tami A.E., Nasser P., Schaffler M.B., Tate M.L.K. Noninvasive fatigue fracture model of the rat ulna. J Orthop Res 2006, 21:1018.
21. Burr D.B., Hooser M. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 1995, 17:431.
22. Ritchie R.O., Koester K.J., Ionova S., Yao W., Lane N.E., Ager J.W. Measurement of the toughness of bone: a tutorial with special reference to small animal studies. Bone 2008, 43:798.
23. ASTM Standard E-399 Standard test method for linear-elastic plane-strain fracture toughness KIC of metallic materials 2006, American Society for Testing and Materials, West Conshohocken, PA.
24. Kruzic J.J., Kuskowski S.J., Ritchie R.O. Simple and accurate fracture toughness testing methods for pyrolytic carbon/graphite composites used in heart-valve prostheses. J Biomed Mater Res A 2005, 74A:461-464.
25. ASTM Standard E-1820 Standard test method for measurement of fracture toughness 2006, West Conshohocken, PA: American Society for Testing and Materials; 2006.
26. Zahoor A. Ductile fracture handbook 1989, Electric Power Research Institute, Palo Alto.
27. Takahashi Y. Evaluation of leak-before-break assessment methodology for pipes with a circumferential through-wall crack. Part I: stress intensity factor and limit load solutions. Int J Press Vessels Piping 2002, 79:385.
28. Duvall C.L., Taylor W.R., Weiss D., Wojtowicz A.M., Guldberg R.E. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res 2006, 22:286-297.
29. Thurner P.J., Chen C.G., Ionova-Martin S., Sun L., Harman A., Porter A., et al. Osteopontin deficiency increases bone fragility but preserves bone mass. Bone 2010, 46:1564-1573.
30. Rajachar R.M., Chow D.L., Curtis C.E., Weissman N.A., Kohn D.H. Acoustic emission: standards and technology update. Use of acoustic emission to characterize focal and diffuse microdamage in bone 1999, West Conshohocken: American Society for Testing and Materials; 1999. S.J. V (Ed.).
31. Zioupos P., Currey J.D. Changes in the stiffness, strength, and toughness of human cortical bone with age. Bone 1998, 22:57-66.
32. Bonadio J., Saunders T.L., Tsai E., Goldstein S.A., Morris-Wiman J., Brinkley L., et al. Transgenic mouse model of the mild dominant form of osteogenesis imperfecta. Proc Natl Acad Sci U S A 1990, 87:7145.
33. Jepsen K., Schaffler M.B., Kuhn J.L., Goulet R.W., Bonadio J., Goldstein S.A. Type I collagen mutation alters the strength and fatigue behavior of Mov13 cortical tissue. J Biomech 1997, 30:1141.
34. Uveges T.E., Kozloff K.M., Ty J.M., Ledgard F., Raggio C.L., Gronowicz G., et al. Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res 2009, 24:849-859.
35. Boyde A., Travers R., Glorieux F.H., Jones S.J. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 1999, 64:185.
36. Currey J. The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech 1996, 29:257.
37. Dong X., Guda T., Millwater H., Wang X. Probabilistic failure analysis of bone using a finite element model of mineral-collagen composites. J Biomech 2009, 42:202.
38. Burr D., Miller L., Grynpas M., Li J., Boyde A., Mashiba T., et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003, 33:960.
39. Ruppel M., Burr D., Miller L. Chemical makeup of microdamaged bone differs from undamaged bone. Bone 2006, 39:318.
40. Timlin J.A., Carden A., Morris M.D., Rajachar R.M., Kohn D.H. Raman spectroscopic imaging markers for fatigue-related microdamage in bovine bone. Anal Chem 2000, 72:2229-2236.
41. Danova N.A., Colopy S.A., Radtke C.L., Kalscheur V.L., Markel M.D., Vanderby R., et al. Degradation of bone structural properties by accumulation and coalescence of microcracks. Bone 2003, 33:197-205.
42. Burr D.B., Martin R.B., Schaffler M.B., Radin E.L. Bone remodeling in response to in vivo fatigue microdamage. J Biomech 1985, 18:189-200.
43. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004, 19:999-1005.
44. Li J., Mashiba T., Burr D.B. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001, 69:281-286.
45. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
46. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
47. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 2008, 82:354-360.